A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910